ImmunityBio (IBRX) Profit After Tax Growth (1y) (2015 - 2026)

ImmunityBio (IBRX) Profit After Tax Growth (1y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 0.26%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -107.76%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 101.22%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 ImmunityBio 7.22 Bn 6.84 Bn 43.97 Mn -388.01%

Historic Data

Download Data
DateValue
Mar 31, 2026 -388.01%
Dec 31, 2025 -4.57%
Sep 30, 2025 21.57%
Jun 30, 2025 31.21%
Mar 31, 2025 3.33%
Dec 31, 2024 74.64%
Sep 30, 2024 10.28%
Jun 30, 2024 2.63%
Mar 31, 2024 -15.05%
Dec 31, 2023 -115.45%
Sep 30, 2023 14.01%
Jun 30, 2023 -45.74%
Mar 31, 2023 -13.19%
Dec 31, 2022 -14.85%
Sep 30, 2022 -25.71%
Jun 30, 2022 -6.10%
Mar 31, 2022 -27.98%
Dec 31, 2021 -193.53%
Sep 30, 2021 -34.79%
Jun 30, 2021 -71.84%